Market Cap 64.22M
Revenue (ttm) 178.03M
Net Income (ttm) -70.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.77%
Debt to Equity Ratio -0.68
Volume 429,807
Avg Vol 1,177,364
Day's Range N/A - N/A
Shares Out 265.05M
Stochastic %K 20%
Beta 2.24
Analysts Sell
Price Target $1.62

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 12 3543 0000
Address:
60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom
Stockseeking
Stockseeking Jun. 17 at 5:47 PM
$ADAP only green in the red sea
0 · Reply
Dardpro
Dardpro Jun. 17 at 12:49 PM
$ADAP i'm back babess, time to buy yet?
1 · Reply
mrdoing
mrdoing Jun. 17 at 5:22 AM
$ADAP ohhhh ohhhhh ohhhhh ohhhhh
0 · Reply
GickyRervais
GickyRervais Jun. 16 at 8:45 PM
$ADAP For those thinking “cash is tight but we can squeeze through for two more years”: Jonathan Chang So I guess, just synthesizing all of that together, do you believe you have sufficient cash today to get to your goal of being profitable in 2027? Or does it assume...? Adrian Rawcliffe No, let's -- we said that last year. That remains the case now.
1 · Reply
Joe_90_
Joe_90_ Jun. 16 at 8:23 PM
$ADAP i'm basically writing off my investment and will use it as a tax loss, pity i believed the management and pumpers, from reading the thread it doesnt bode well, management are fine they'll have their philli sandwiches but the employees wont fair as well i expect. Pity.
1 · Reply
mrdoing
mrdoing Jun. 16 at 2:22 PM
0 · Reply
Mogeyman
Mogeyman Jun. 16 at 11:35 AM
0 · Reply
GickyRervais
GickyRervais Jun. 15 at 8:56 PM
$ADAP Colleagues in the pharmaceutical business say it is really, really tough out there. No funding sources for companies of any stage let alone commercial, layoffs and countless delays. Zero chance of an ex-bankruptcy deal here.
3 · Reply
Stockseeking
Stockseeking Jun. 15 at 8:40 PM
$ADAP 2025 expected revenue between 35-45 millions. Q1 4M, meaning an average of 8-10 m for each of the remaining Q. Expect Q2 revenue of at least 8 m as 8 patients invoiced before May13rd. R&D and SG&A will do down in Q2 due to re-structuring. Late-cell BLA rolling submission 2025 Q4. Cash is tight, but just need to manage through about 1-2 years, then adap turns the corner with two approved products, increasing revenues based on the same qualified treatment center.
1 · Reply
Haydenb323
Haydenb323 Jun. 15 at 10:17 AM
$ADAP When a company gives its CFO a fixed “stay-until” date that’s only a few months away, it usually means the board expects a discrete transaction to close inside that window and then won’t need two finance chiefs. Adaptimmune pushed Gavin Wood’s exit from 31 May to 31 Aug 2025 under a short extension agreement—after which his employment automatically ends . The footnotes of its 2024 10-K already flagged a cost-cutting restructuring and said Wood would step down once “strategic alternatives” were settled . While the March-quarter 10-Q warns of “substantial doubt” about going-concern status , the company has not filed—or prepared the paperwork—for a Chapter 11, and it just prepaid part of its Hercules loan, a move lenders seldom allow when a filing is imminent .
3 · Reply
Latest News on ADAP
Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 20, 2025, 7:00 AM EDT - 3 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update


Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 4:05 PM EST - 7 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates


Adaptimmune to Participate in Two Bank Conferences this September

Aug 28, 2024, 8:00 AM EDT - 10 months ago

Adaptimmune to Participate in Two Bank Conferences this September


Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 12, 2024, 7:00 AM EDT - 11 months ago

Adaptimmune Reports Q2 2024 Financial and Business Updates


Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates


Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech


Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 29, 2023, 8:00 AM EST - 1 year ago

Adaptimmune Receives Transfer of IND for Lete-cel Program


Adaptimmune: Spinning Sarcoma Into Gold

Sep 12, 2023, 8:48 AM EDT - 1 year ago

Adaptimmune: Spinning Sarcoma Into Gold


Stockseeking
Stockseeking Jun. 17 at 5:47 PM
$ADAP only green in the red sea
0 · Reply
Dardpro
Dardpro Jun. 17 at 12:49 PM
$ADAP i'm back babess, time to buy yet?
1 · Reply
mrdoing
mrdoing Jun. 17 at 5:22 AM
$ADAP ohhhh ohhhhh ohhhhh ohhhhh
0 · Reply
GickyRervais
GickyRervais Jun. 16 at 8:45 PM
$ADAP For those thinking “cash is tight but we can squeeze through for two more years”: Jonathan Chang So I guess, just synthesizing all of that together, do you believe you have sufficient cash today to get to your goal of being profitable in 2027? Or does it assume...? Adrian Rawcliffe No, let's -- we said that last year. That remains the case now.
1 · Reply
Joe_90_
Joe_90_ Jun. 16 at 8:23 PM
$ADAP i'm basically writing off my investment and will use it as a tax loss, pity i believed the management and pumpers, from reading the thread it doesnt bode well, management are fine they'll have their philli sandwiches but the employees wont fair as well i expect. Pity.
1 · Reply
mrdoing
mrdoing Jun. 16 at 2:22 PM
0 · Reply
Mogeyman
Mogeyman Jun. 16 at 11:35 AM
0 · Reply
GickyRervais
GickyRervais Jun. 15 at 8:56 PM
$ADAP Colleagues in the pharmaceutical business say it is really, really tough out there. No funding sources for companies of any stage let alone commercial, layoffs and countless delays. Zero chance of an ex-bankruptcy deal here.
3 · Reply
Stockseeking
Stockseeking Jun. 15 at 8:40 PM
$ADAP 2025 expected revenue between 35-45 millions. Q1 4M, meaning an average of 8-10 m for each of the remaining Q. Expect Q2 revenue of at least 8 m as 8 patients invoiced before May13rd. R&D and SG&A will do down in Q2 due to re-structuring. Late-cell BLA rolling submission 2025 Q4. Cash is tight, but just need to manage through about 1-2 years, then adap turns the corner with two approved products, increasing revenues based on the same qualified treatment center.
1 · Reply
Haydenb323
Haydenb323 Jun. 15 at 10:17 AM
$ADAP When a company gives its CFO a fixed “stay-until” date that’s only a few months away, it usually means the board expects a discrete transaction to close inside that window and then won’t need two finance chiefs. Adaptimmune pushed Gavin Wood’s exit from 31 May to 31 Aug 2025 under a short extension agreement—after which his employment automatically ends . The footnotes of its 2024 10-K already flagged a cost-cutting restructuring and said Wood would step down once “strategic alternatives” were settled . While the March-quarter 10-Q warns of “substantial doubt” about going-concern status , the company has not filed—or prepared the paperwork—for a Chapter 11, and it just prepaid part of its Hercules loan, a move lenders seldom allow when a filing is imminent .
3 · Reply
zahnan
zahnan Jun. 15 at 6:27 AM
$ADAP looks like the long thesis is that someone might rescue the company before cash runs out, essentially a gamble with terrible odds... good luck
0 · Reply
ViVega1
ViVega1 Jun. 14 at 11:58 AM
$ADAP Don't like the move down on friday. Is there something lurking around the corner? ADAP was and is my favorite play in biotechs but I'm not lucky with the situation.
0 · Reply
JustEk33
JustEk33 Jun. 14 at 10:15 AM
$ADAP can the C suite and BoD please take a vacation?? With all the stellar pipeline execution, partnerships kept, impeccable management of cash burn from the CFO achem… CEO, and the publicly stated timelines achieved. We shareholders wouldn’t want you to burn out and not be able to continue this recent domination as the “clear leaders in the TCR space”…you know; as evidenced below 🤷‍♂️
0 · Reply
JustEk33
JustEk33 Jun. 13 at 11:49 PM
$ADAP my uncle Rico can throw a football clear over a Colorado mountain. Just like Adrian will execute on any ONE of his promises
1 · Reply
Bionco
Bionco Jun. 13 at 10:16 PM
$ADAP Anne Wojcicki to buy back 23andMe and its data for $305 million https://www.cnbc.com/2025/06/13/anne-wojcicki-to-buy-back-23andme-and-its-data-for-305-million.html?__source=androidappshare
1 · Reply
BlockheadCapital
BlockheadCapital Jun. 13 at 8:15 PM
$ADAP pretty soon my cousin Greg will be able to rescue the firm
1 · Reply
mrdoing
mrdoing Jun. 13 at 6:55 PM
0 · Reply
mrdoing
mrdoing Jun. 13 at 2:21 PM
0 · Reply
AS1980
AS1980 Jun. 13 at 2:13 PM
$ADAP red? Can’t believe this 🤣🤣
0 · Reply
Stockseeking
Stockseeking Jun. 13 at 10:32 AM
$ADAP still believe Galapagos will rescue adap in some forms. Why not to get one marketed product and one BLA ready
5 · Reply
mrdoing
mrdoing Jun. 13 at 8:38 AM
1 · Reply
Polip
Polip Jun. 12 at 8:57 PM
0 · Reply